Aggressive Pursuit of No Evidence of Disease Status in Hepatoblastoma Improves Survival

Study Design and Population

Cincinnati Children's Hospital reviewed 50 hepatoblastoma patients treated between 2005 and 2021, examining whether aggressive surgical pursuit of no evidence of disease (NED) status affects survival outcomes 0:00 0:35. The cohort included both high-risk and non-high-risk patients stratified by standard criteria 0:20.

Primary Findings

Forty-one of 50 patients achieved NED status through aggressive surgical intervention 0:42. Both overall survival and event-free survival improved significantly in patients who reached NED status, with the benefit observed across both high-risk and non-high-risk subgroups 0:48. The implication is that complete surgical clearance of disease—including repeated metastasectomies when indicated—confers a survival advantage even in high-risk hepatoblastoma 0:58.

Clinical Application

The data support an aggressive surgical approach to hepatoblastoma metastases rather than accepting residual disease after initial resection 0:48 0:58. This likely means pursuing pulmonary metastasectomy, repeat hepatic resection, or other interventions to achieve complete radiographic clearance 0:42. The study timeframe suggests this strategy is durable, not just a short-term observation 0:00.

What This Changes

For hepatoblastoma, the threshold for declaring a patient unresectable or accepting residual disease after chemotherapy should be high 0:58. If NED status is achievable through additional surgery—even complex or staged procedures—this study suggests it is worth pursuing 0:42 0:48. The survival benefit held in high-risk patients, the group most likely to have been considered for less aggressive management in prior eras 0:48.

Limitations

This is a single-center retrospective study without a control arm randomized to less aggressive management 0:00 0:35. Selection bias is inherent: patients who achieved NED status may have had more favorable biology independent of surgical aggressiveness 0:42 0:48. The study does not define "aggressive pursuit" operationally—how many metastasectomies, what intervals, what imaging thresholds—so replicating the approach requires institutional judgment 0:35. Morbidity data from the aggressive surgical strategy are not reported here 0:35.